RATIONALES FOR TREATING IgA NEPHROPATHIES

Wardle, E. N.

doi:10.1081/jdi-100100846

Cited by 4 publications

(1 citation statement)

References 93 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The pathogenesis of this disease has not been fully established yet. However, many therapeutic maneuvers have been undertaken, among them supplementation with polyunsaturated fatty acids was advocated [5][6][7]. Our study also supports these findings [8,9].…”

Section: Introductionsupporting

confidence: 89%

Effect of 12-Month Therapy with Omega–3 Polyunsaturated Acids on Glomerular Filtration Response to Dopamine in IgA Nephropathy

Sulikowska

Nieweglowski²,

Manitius³

et al. 2004

Am J Nephrol

View full text Add to dashboard Cite

Background: ω–3 polyunsaturated acids therapy is efficient in primary IgA nephropathy. It is unknown whether doses of ω–3 smaller than those given previously are still effective. The aim of the study was to examine the effect of ω–3 therapy on renal vascular function in relation to proteinuria and urinary excretion of N-acetyl-β-D-glucosaminidase (NAG). Methods: 20 IgA patients aged 36.5 ± 10.77 with creatinine clearance (Cr_cl) 105.71 ± 27.3 ml/min and proteinuria 3.31 ± 2.01 g/24 h were given orally 810 mg EPA and 540 mg DHA daily for 12 months. Before and at the end of the study, 24-hour proteinuria, serum homocysteine, and Cr_cl were measured. At the same time, renal vascular function was estimated as dopamine-induced glomerular filtration response (DIR). DIR was measured as: two 120-min lasting Cr_cl (before and during 2 µg/kg b.w./min i.v. dopamine). Results: The results obtained during follow-up were as follows (baseline vs. after therapy): DIR 14.9 ± 16.4 vs. 30.3 ± 14.3% (p < 0.01); urine protein 2.31 ± 2.01 vs. 1.31 ± 1.37 g/24 h (p < 0.01); (Cr_cl) 105.71 ± 27.3 vs. 103.9 ± 20.9 ml/min (n.s.); NAG 8.3 ± 1.8 vs. 6.0 ± 1.2 U/g_creat (p < 0.01), and homocysteine 16.2 ± 3.15 vs. 13.8 ± 2.6 µmol/l (p < 0.05). The only correlation found was linear correlation between basal DIR and DIR change (r = –0.570; p < 0.010) and basal NAG (r = –0.460; p < 0.50). Conclusions: ω–3 supplementation is associated with the improvement of both renal vascular function and tubule function.

show abstract

Section: Introductionsupporting

confidence: 89%

Effect of 12-Month Therapy with Omega–3 Polyunsaturated Acids on Glomerular Filtration Response to Dopamine in IgA Nephropathy

Sulikowska

Nieweglowski²,

Manitius³

et al. 2004

Am J Nephrol

View full text Add to dashboard Cite

show abstract

Docosahexaenoic Acid and Eicosapentaenoic Acid, but Not α-Linolenic Acid, Suppress Deoxynivalenol-Induced Experimental IgA Nephropathy in Mice

Jia

Shi

Bennink

et al. 2004

The Journal of Nutrition

View full text Add to dashboard Cite

Diets enriched in the (n-3) PUFAs, docosahexaenoic acid (DHA), eicosapentaenoic acid (EPA), and their precursor alpha-linolenic acid (ALA), were evaluated for efficacy in ameliorating the development of IgA nephropathy (IgAN) induced in mice by the mycotoxin deoxynivalenol (DON). The effects of DON were compared in mice that were fed for 18 wk with AIN-93G diets containing 1) 10 g/kg corn oil plus 60 g/kg oleic acid (control); 2) 10 g/kg corn oil plus 35 g/kg oleic acid and 25 g/kg DHA-enriched fish oil (DHA); 3) 10 g/kg corn oil plus 33 g/kg oleic acid and 27 g/kg EPA-enriched fish oil (EPA); and 4) 10 g/kg corn oil plus 37 g/kg oleic acid and 23 g/kg DHA + EPA (1:1) enriched fish oil (DHA + EPA). The DHA, EPA and DHA + EPA diets attenuated induction by dietary DON (10 mg/kg) of serum IgA and IgA immune complexes, kidney mesangial IgA deposition, and ex vivo IgA secretion by spleen cells. Consumption of the DHA + EPA diet for 8 wk significantly abrogated the DON-induced gene expression of interleukin (IL)-6, a requisite cytokine for DON-induced IgA nephropathy, in spleen and Peyer's patches. Finally, incorporation of ALA-containing flaxseed oil up to 60 g/kg in the AIN-93G diet did not affect DON-induced IgA dysregulation in mice. Taken together, both DHA and EPA, but not ALA, ameliorated the early stages of IgAN, and these effects might be related to a reduced capacity for IL-6 production.

show abstract

Renal protection in immunoglobulin-A nephropathy

Wardle¹

2005

Nephrology Dialysis Transplantation

View full text Add to dashboard Cite

RATIONALES FOR TREATING IgA NEPHROPATHIES

Cited by 4 publications

References 93 publications

Effect of 12-Month Therapy with Omega–3 Polyunsaturated Acids on Glomerular Filtration Response to Dopamine in IgA Nephropathy

Effect of 12-Month Therapy with Omega–3 Polyunsaturated Acids on Glomerular Filtration Response to Dopamine in IgA Nephropathy

Docosahexaenoic Acid and Eicosapentaenoic Acid, but Not α-Linolenic Acid, Suppress Deoxynivalenol-Induced Experimental IgA Nephropathy in Mice

Renal protection in immunoglobulin-A nephropathy

Contact Info

Product

Resources

About